GSK-1120212 - CAS 871700-17-3

Trametinib(cas# 871700-17-3), also known as GSK1120212, is a n orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth. On May 29, 2013, FDA approved T rametinib.

Catalog Number: A000905

CAS Number: 871700-17-3

PubChem Substance ID:350078979

Molecular Formula: C₂₆H₂₃FIN₅O₄

Molecular Weight:615.39

Purity: ≥95%

* For research use only. Not for human or veterinary use.


SynonymsJTP-74057; GSK1120212


Molecular Formula: C₂₆H₂₃FIN₅O₄
Molecular Weight615.39
Solubility10 mM in DMSO
Storage3 years -20C powder
Overview of Clinical ResearchOriginator: Japan Tobacco<br /> Developer: Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center<br /> Class: 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules<br /> Mechanism of Action: MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors<br /> Orphan Drug Status: Yes – Malignant melanoma<br />
IC500.92 nM/1.8 nM (MEK1/2)

Computed Descriptor